INSIGHT. Peptides (short chains of amino acids) have long been used in the development of pharmaceuticals, such as diabetes medicine. In recent years, we’ve seen a dramatic increase in peptide-based pharmaceuticals.
In 2022, peptide pharmaceuticals accounted for 5 percent of the global pharmaceutical market, with a market value of USD 42.05 billion and an expected compound annual growth rate (CAGR) of 10 percent from 2023 to 2032.
Currently, there are 80 peptide drugs that are approved for treatment and more than 200 peptides are in clinical development. Regulatory approval and the growing demand for new treatments for chronic diseases have driven increased research and investments in peptide-based treatments.
Peptides have many useful medicinal properties, making them attractive options in the treatment of various diseases. The unique ability of peptides to interact with specific receptors makes them particularly effective. Peptide-based pharmaceuticals also have fewer side effects compared to traditional pharmaceuticals. Take, for example, semaglutide. This is a synthetic version of the natural hormone GLP-1 – which plays a key role in blood sugar level regulation and appetite suppression – and has received extensive media attention for its effects on obesity and cardiovascular disease. Once semaglutide was approved in the USA for the treatment of obesity, demand became so great that there are now global shortages of the drug.
The large pharmaceutical player Novo Nordisk has developed several ground-breaking peptide-based pharmaceuticals, including Ozempic and Rybelsus, and competitors such as Eli Lilly are trying to keep up. In addition to diabetes, obesity and cardiovascular disease, peptides are being studied for their anti-inflammatory properties and potential within cancer treatment.
Receive news and invitations from Sciety
Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.
